


NOVEMBER 03, 2014

Company Name	Suven Life Science
Sector	Pharma
CMP	225
Target	270+

Fundamental Key

Market Cap (in Cr.)	2628.07
Earning Per Share	12.76
Price To Earning Ratio	17.63
Book Value Per Share	22.65
Price to Books (P/B) Ratio	9.94
EBIT Margin (%)	41.77
PAT Margin (%)	28.23
ROCE (%)	68.07
PAT Growth (%)	367.44
Total Debt to Equity (D/E) Ratio	0.34

Suven Life Sciences's Shareholding Pattern

Description	Percent of Share (%)
Promoters	63.44
Individuals	26.49
Institutions	0.01
FII	0.07
Govt.	0.00
Others	9.99

Market News :

Suven commences Phase I trials of drug for Alzheimer's treatment

Suven Life Sciences Ltd has been granted product patent from the US and South Korea for its new chemical entity (NCE) used in the treatment.